Abstract:Abstract Background and Aims To determine the degree of influence of endothelial dysfunction on the hemodynamics of renal and central vessels in respiratory pathology, as well as to determine the effectiveness of complex therapy regimens with carvedilol. Method Studies were conducted in 26 patients with chronic obstructive pulmonary disease (COPD) of II- III severity (group 1, in whom the level of glomerular filtration rate of the kidneys eGFR CKD-EPI ≥6 ml/min/1.73 m2 was determined) and 32 patients with COPD of IV severity (group 2, they were determined e GFR CKD-EPI ≥60 ml/min/1.73 m2). Patients received one course of ten-day standard therapy (GOLD, 2020) in combination with a beta–blocker drug, T. carvedilol 5 mg (Vertex). Doppler echocardiographic examination of peripheral vessels, heart and renal vessels of patients was performed. Stable metabolites of nitric oxide (Cm NO) in blood plasma, ventilation and perfusion state of the lungs were determined. Results A significant decrease in the functional state of the respiratory system was parallel with a decrease in Cm NO synthesis, which was clearly reflected in the second group (by 11%) compared with the first group (by 7%). Pronounced structural changes with remodeling of the right parts of the heart, as well as a pronounced degree of pancreatic hypertrophy in the second group were accompanied by a sharp change in renal filtration function (eGFR ≤60 ml/min/1.73 m2). When measuring the state of diastolic dysfunction of the right parts of the heart, a decrease in E/As well as an increase in the circulatory vascular resistance index and mean blood pressure were significantly higher in the first group of patients (where еGFR ≥6 ml/min/1.73 m2). After a course of treatment with t. carvedilol, based on basic treatment, normalization of endothelial function was determined, reflected in an increase in the concentration of stable metabolites of nitric oxide by 1.05 and 1.5 times (p<0.05) in the biological fluid, respectively, in the first and second groups. In the dynamics of the course of therapy in groups of patients with 75% and 35% decrease in lung ventilation capacity, mean pulmonary arterial pressure decreased by 18.1 and 14.3%, respectively, and the hemodynamic resistance index decreased by 7.9% and 5.7% in parallel (p<0.05). Conclusion When monitoring the functional state of central and renal hemodynamics and ventilation-perfusion function of the bronchopulmonary system after complex treatment with carvedilol, a long-term hypotensive effect, a decrease in endothelial dysfunction, respectively, and an improvement in central and renal hemodynamics were determined.

Tolerance of Carvedilol Treatment in Elderly Patients with Chronic Heart Failure

Tolerance and Safety Study of Carvedilol (ilatrend)treatment in 482 Patients with Mild and Moderate Stable Chronic Heart Failure

Carvedilol and Its New Analogs Suppress Arrhythmogenic Store Overload–induced Ca2+ Release

Effects of Carvedilol on Circulating Levels of Endothelin and Von Willebrand Factor in Patients with Unstable Angina Pectoris

Effectiveness of Carvedilol on Serum Hs-Crp, NT-proBNP, MMP-9 and Cardiac Function in Patients with Chronic Heart Failure

Clinical efficacy observation of Amiodarone and Metoprolol on elderly paients with coronary heart disease by cardiac arrhythmias

Role of Losartan and Carvedilol on in Extracellular Signal-Regulated Kinases in Myocardium of Spontaneously Hypertensive Rats

Comparison Of Low And High Doses Of Carvedilol On Restoration Of Cardiac Function And Calcium-Handling Proteins In Rat Failing Heart

Therapeutic efficacy of carvedilol in essential hypertension

The Clinical Application of Carvedilol in the Treatment of Dilated Cardiomyopathy Heart Failure

Effects of Carvedilol on the Renal Function in Patients with Essential Hypertension

Treatment of Carvedilol for Refractory Hypertension in Patients with Renal Diseases: A Multicentre, Prospective Clinical Trial

Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol

Multi-center Trial of Carvedilol (dilatrend) Treatment for Resistant Renal Parenchymal Hypertension

Comparison of Clinical Efficacies in Carvedilol,Bisoprolol and Conventional Therapies for Patients with Chronic Heart Failure

[The Effect of Carvedilol on Apoptosis Gene PDCD5 Expression in Chronic Heart Failure Patients].

Long-term outcome of carvedilol therapy in Japanese patients with nonischemic heart failure

Effect of Carvedilol and Metoprolol on Blood Pressure, Blood Flow, and Vascular Resistance

Endothelial Phenotype Evoked by Low Dose Carvedilol in Pulmonary Hypertension

#1073 Changes in endothelial function in patients with impaired central and renal hemodynamics respiratory pathology

Effect of Carvedilol on the Stability of Plasma Catecholamine in Patients with Myocardial Infarction